Clinic
Methodist Hospitals of Dallas
Methodist Hospitals of Dallas was paid $2.65M by Medicaid between Jan 2020 and Dec 2024, across 89 billing codes. Its largest line is 99283, emergency room visit (moderate) — 29% of everything it billed.
33Billing provider infoMETHODIST HOSPITALS OF DALLAS
RICHARDSON, TX 75082
RICHARDSON, TX 75082
33aNPI1033165501assigned 05/26/2006
33bProvider typeMammography Clinic/Center
28Total paid$2.65M
24GClaims109,569
24DCodes billed89
24AFirst – last monthJan 2020 – Dec 2024
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2020 | 1,808 | $33K | |
| 2021 | 22,655 | $468K | |
| 2022 | 32,712 | $879K | |
| 2023 | 31,413 | $841K | |
| 2024incomplete | 20,981 | $426K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 29% | 10,111 | 9,354 | $760K |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 16% | 2,895 | 2,689 | $415K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 5.6% | 1,285 | 1,176 | $148K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 4.1% | 3,307 | 2,960 | $109K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 4.0% | 580 | 544 | $105K |
| G0378 | Hospital observation service, per hour | 3.8% | 495 | 367 | $100K |
| 80053 | Comprehensive metabolic panel | 3.3% | 9,051 | 6,917 | $88K |
| 70450 | Computed tomography, head or brain; without contrast material | 2.9% | 1,257 | 1,159 | $77K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 2.6% | 1,786 | 1,660 | $69K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 2.5% | 11,393 | 8,138 | $67K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.5% | 1,703 | 1,601 | $66K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 2.4% | 2,100 | 1,931 | $63K |
77 more codes
| 71045 | Radiologic examination, chest; single view | 2.4% | 3,628 | $63K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 2.2% | 1,178 | $58K |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | 2.1% | 1,300 | $57K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 2.0% | 464 | $53K |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.4% | 1,848 | $36K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 1.3% | 239 | $34K |
| 80050 | General health panel | 1.2% | 321 | $32K |
| 83880 | <1% | 1,446 | $23K | |
| 84484 | <1% | 3,219 | $17K | |
| 84703 | <1% | 2,363 | $16K | |
| 80143 | <1% | 818 | $14K | |
| 81001 | <1% | 3,633 | $13K | |
| 80179 | <1% | 810 | $12K | |
| 83690 | <1% | 2,215 | $9K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 608 | $9K |
| 80320 | <1% | 738 | $9K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 405 | $8K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 1,557 | $8K |
| 87430 | <1% | 350 | $7K | |
| 76801 | <1% | 84 | $7K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 237 | $7K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 946 | $7K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 1,054 | $6K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 248 | $6K |
| 83735 | <1% | 2,363 | $6K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 958 | $5K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 126 | $5K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 2,828 | $4K |
| 85610 | <1% | 1,993 | $3K | |
| 83605 | <1% | 808 | $3K | |
| 86850 | <1% | 370 | $3K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 102 | $3K |
| 84702 | <1% | 196 | $3K | |
| 85730 | <1% | 1,253 | $3K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 103 | $2K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 31 | $2K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 1,408 | $2K |
| 87807 | <1% | 66 | $2K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 66 | $2K |
| 86769 | <1% | 90 | $2K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 2,128 | $2K |
| 81003 | <1% | 1,111 | $2K | |
| 86900 | <1% | 977 | $1K | |
| 86901 | <1% | 973 | $1K | |
| 84145 | <1% | 212 | $1K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 1,354 | $1K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 17 | $1K |
| 85379 | <1% | 204 | $1K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 1,079 | $917.38 |
| 87040 | <1% | 195 | $742.71 | |
| 84100 | <1% | 595 | $699.95 | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 895 | $658.94 |
| 87081 | <1% | 78 | $627.28 | |
| 82728 | <1% | 163 | $626.80 | |
| 87186 | <1% | 129 | $604.52 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 1,963 | $363.92 |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 106 | $358.80 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 643 | $280.54 |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 16 | $274.14 |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 150 | $271.00 |
| 87077 | <1% | 40 | $237.79 | |
| 86140 | <1% | 71 | $216.34 | |
| 83615 | <1% | 98 | $196.72 | |
| 87088 | <1% | 26 | $173.85 | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 23 | $87.74 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 173 | $71.58 |
| 82962 | <1% | 4,349 | $58.10 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 95 | $53.53 |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 34 | $24.25 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 62 | $17.70 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 15 | $2.07 |
| J8499 | Prescription drug, oral, non chemotherapeutic, nos | <1% | 2,899 | $0.76 |
| J3490 | Unclassified drugs | 0% | 128 | $0.00 |
| 36415 | Collection of venous blood by venipuncture | 0% | 69 | $0.00 |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | 0% | 39 | $0.00 |
| 96376 | 0% | 15 | $0.00 | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 0% | 12 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialBJERKE, CRAIG (EXECUTIVE VP & CFO)
| Provider | Location | Paid |
|---|---|---|
| Methodist Hospitals of Dallas | Dallas, TX | $13.18M |
| Methodist Hospitals of Dallas | Dallas, TX | $12.59M |
| Methodist Hospitals of Dallas | Mansfield, TX | $3.20M |
| Methodist Hospitals of Dallas | Midlothian, TX | $2.35M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.